[ACCESSWIRE]
BEDMINSTER, NJ / ACCESSWIRE / October 5, 2015 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious diseases, today announced highlights from two sponsored abstracts for poster presentation at the American Society of Nephrology Kidney Week 2015. The data to be presented highlight the potential cost savings from reducing infections and thrombosis in hemodialysis patients with central venous catheters (CVCs).
"Complications from long-term catheter use can lead to treatment delays and increased costs to the healthcare system due to hospitalizations, need for additional treatment, and/or removal or replacement of the catheter," said Randy Milby, CEO, CorMedix. "CorMedix is proud to sponsor the abstracts, prepared by DaVita Clinical Research, which highlight the potential cost savings to providers and payers from reducing complications in hemodialysis patients with CVCs. We look forward to presenting the full data at the American Society of Nephrology Kidney Week meeting next month."
The abstracts submitted and selected for poster presentation include:
Economic Burden to Dialysis Providers of Central Venous Catheter (CVC)-Related Blood Stream Infections (BSI) and Occlusions Among Incident Hemodialysis (HD) Patients
Session Title: Hemodialysis Vascular Access: From Bench to Bedside
Session Date, Time:Thursday, November 5, 2015, 10:00 AM - 12:00 PM
The results demonstrated that CVC-related bloodstream infections were associated with significantly greater erythropoiesis-stimulating agent (ESA) utilization, intravenous antibiotic use and missed hemodialysis treatments. This translated into a mean incremental cost of $397 per patient per month. CVC was also associated with increased thrombolytic use but no significant difference in costs. CVC-related BSI is a potent cost driver for dialysis providers with incremental costs of approximately $400 per month over a six-month time horizon, while no appreciable economic consequences of CVC occlusion were observed.
Economic Burden to Medicare of Central Venous Catheter (CVC)-Related Blood Stream Infections (BSI) and Occlusions Among Incident Hemodialysis (HD) Patients
Session Title: Hemodialysis Vascular Access: From Bench to Bedside
Session Date, Time:Thursday, November 5, 2015, 10:00 AM - 12:00 PM
The results demonstrated that CVC-related bloodstream infections were associated with greater hospitalizations and vascular related procedures. The mean per patient per month costs were $2624 higher for BSI patients versus controls, driven by increased inpatient costs. CVC occlusion was associated with modestly greater rates of hospitalization, but substantially greater risk of ambulatory procedures. The mean per patient per month costs were $2354 greater for occlusion patients versus controls, driven by higher ancillary service and procedure costs. CVC-BSI and occlusion are potent cost drivers for Medicare. Risk-mitigation strategies to prevent BSIs and occlusions should prove to reduce systemic healthcare costs.
About CorMedix Inc.
CorMedix Inc. is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiorenal and infectious diseases. CorMedix's first commercial product in Europe is Neutrolin(R), a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval. For more information, visit www.cormedix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the unpredictability of the estimated costs and savings estimated to be related to central venous catheter related bloodstream infections and related medical conditions; the unpredictability of the markets for, and market acceptance of, Neutrolin;the outcome of clinical trials of CorMedix's product candidates, including Neutrolin, and whether they demonstrate these candidates' safety and effectiveness; the cost, timing and results of the planned Phase 3 trial for Neutrolin in the U.S.; and obtaining additional financing to support CorMedix's research and development and clinical activities and operations. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contact:
Investors:
CorMedix Inc.
Randy Milby
(908) 517-9489
Media:
Mike Beyer
Sam Brown Inc.
(312) 961-2502
[email protected]
SOURCE: CorMedix Inc.
